JP2008502332A - メチル化核酸の分析 - Google Patents
メチル化核酸の分析 Download PDFInfo
- Publication number
- JP2008502332A JP2008502332A JP2007515787A JP2007515787A JP2008502332A JP 2008502332 A JP2008502332 A JP 2008502332A JP 2007515787 A JP2007515787 A JP 2007515787A JP 2007515787 A JP2007515787 A JP 2007515787A JP 2008502332 A JP2008502332 A JP 2008502332A
- Authority
- JP
- Japan
- Prior art keywords
- nucleic acid
- methylated
- sample
- antibody
- methylation
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Pending
Links
- 150000007523 nucleic acids Chemical class 0.000 title claims description 128
- 108020004707 nucleic acids Proteins 0.000 title claims description 75
- 102000039446 nucleic acids Human genes 0.000 title claims description 75
- 238000004458 analytical method Methods 0.000 title abstract description 10
- 238000000034 method Methods 0.000 claims abstract description 89
- 108090000623 proteins and genes Proteins 0.000 claims abstract description 59
- 230000011987 methylation Effects 0.000 claims abstract description 50
- 238000007069 methylation reaction Methods 0.000 claims abstract description 50
- 201000010099 disease Diseases 0.000 claims abstract description 20
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 claims abstract description 20
- 206010028980 Neoplasm Diseases 0.000 claims abstract description 14
- 201000011510 cancer Diseases 0.000 claims abstract description 12
- 108020004414 DNA Proteins 0.000 claims description 52
- 108700028369 Alleles Proteins 0.000 claims description 34
- 239000012634 fragment Substances 0.000 claims description 29
- 230000027455 binding Effects 0.000 claims description 25
- 239000002777 nucleoside Substances 0.000 claims description 22
- 150000003833 nucleoside derivatives Chemical class 0.000 claims description 21
- 238000001514 detection method Methods 0.000 claims description 15
- 230000014509 gene expression Effects 0.000 claims description 15
- 239000007787 solid Substances 0.000 claims description 14
- 102000004169 proteins and genes Human genes 0.000 claims description 13
- 108091028043 Nucleic acid sequence Proteins 0.000 claims description 12
- 239000000126 substance Substances 0.000 claims description 11
- ZAYHVCMSTBRABG-JXOAFFINSA-N 5-methylcytidine Chemical group O=C1N=C(N)C(C)=CN1[C@H]1[C@H](O)[C@H](O)[C@@H](CO)O1 ZAYHVCMSTBRABG-JXOAFFINSA-N 0.000 claims description 10
- ZAYHVCMSTBRABG-UHFFFAOYSA-N 5-Methylcytidine Natural products O=C1N=C(N)C(C)=CN1C1C(O)C(O)C(CO)O1 ZAYHVCMSTBRABG-UHFFFAOYSA-N 0.000 claims description 9
- 238000003556 assay Methods 0.000 claims description 8
- 239000011324 bead Substances 0.000 claims description 8
- 102100020856 Forkhead box protein F1 Human genes 0.000 claims description 7
- 101000931494 Homo sapiens Forkhead box protein F1 Proteins 0.000 claims description 7
- 101000743808 Homo sapiens Zinc finger protein 677 Proteins 0.000 claims description 7
- 108010032788 PAX6 Transcription Factor Proteins 0.000 claims description 7
- 102100039055 Zinc finger protein 677 Human genes 0.000 claims description 7
- 238000000926 separation method Methods 0.000 claims description 7
- 108091007507 ADAM12 Proteins 0.000 claims description 6
- 102100031112 Disintegrin and metalloproteinase domain-containing protein 12 Human genes 0.000 claims description 6
- 101000658654 Homo sapiens Tetratricopeptide repeat protein 23-like Proteins 0.000 claims description 6
- 101000781608 Homo sapiens WSC domain-containing protein 2 Proteins 0.000 claims description 6
- 102100034910 Tetratricopeptide repeat protein 23-like Human genes 0.000 claims description 6
- 102100036847 WSC domain-containing protein 2 Human genes 0.000 claims description 6
- 230000000694 effects Effects 0.000 claims description 6
- 208000024891 symptom Diseases 0.000 claims description 6
- -1 TGFb2 Proteins 0.000 claims description 5
- YUDSCJBUWTYENI-VPCXQMTMSA-N 4-amino-1-[(2r,3r,4s,5r)-3,4-dihydroxy-5-(hydroxymethyl)-2-methyloxolan-2-yl]pyrimidin-2-one Chemical group C1=CC(N)=NC(=O)N1[C@]1(C)O[C@H](CO)[C@@H](O)[C@H]1O YUDSCJBUWTYENI-VPCXQMTMSA-N 0.000 claims description 3
- 238000011534 incubation Methods 0.000 claims description 3
- 239000007791 liquid phase Substances 0.000 claims description 3
- 102000035195 Peptidases Human genes 0.000 claims description 2
- 108091005804 Peptidases Proteins 0.000 claims description 2
- 231100000504 carcinogenesis Toxicity 0.000 claims description 2
- 235000019833 protease Nutrition 0.000 claims description 2
- 230000001105 regulatory effect Effects 0.000 claims description 2
- 239000013598 vector Substances 0.000 claims description 2
- 102100033798 Homeobox protein aristaless-like 4 Human genes 0.000 claims 5
- 101000779608 Homo sapiens Homeobox protein aristaless-like 4 Proteins 0.000 claims 5
- 101000819111 Homo sapiens Trans-acting T-cell-specific transcription factor GATA-3 Proteins 0.000 claims 4
- 101000964699 Homo sapiens Zinc finger protein 566 Proteins 0.000 claims 4
- 102100037506 Paired box protein Pax-6 Human genes 0.000 claims 4
- 102100021796 Sonic hedgehog protein Human genes 0.000 claims 4
- 101710113849 Sonic hedgehog protein Proteins 0.000 claims 4
- 102100026508 Tafazzin Human genes 0.000 claims 4
- 101710175789 Tafazzin Proteins 0.000 claims 4
- 102100021386 Trans-acting T-cell-specific transcription factor GATA-3 Human genes 0.000 claims 4
- 102100040787 Zinc finger protein 566 Human genes 0.000 claims 4
- 230000007608 epigenetic mechanism Effects 0.000 claims 1
- 230000002401 inhibitory effect Effects 0.000 claims 1
- 230000010309 neoplastic transformation Effects 0.000 claims 1
- 239000008194 pharmaceutical composition Substances 0.000 claims 1
- 230000001225 therapeutic effect Effects 0.000 abstract description 2
- 239000000523 sample Substances 0.000 description 47
- 210000004027 cell Anatomy 0.000 description 37
- 230000007067 DNA methylation Effects 0.000 description 14
- 241000699666 Mus <mouse, genus> Species 0.000 description 14
- 208000029742 colonic neoplasm Diseases 0.000 description 13
- 230000008775 paternal effect Effects 0.000 description 13
- 108091029523 CpG island Proteins 0.000 description 11
- 238000002493 microarray Methods 0.000 description 10
- 239000000725 suspension Substances 0.000 description 10
- XAUDJQYHKZQPEU-KVQBGUIXSA-N 5-aza-2'-deoxycytidine Chemical compound O=C1N=C(N)N=CN1[C@@H]1O[C@H](CO)[C@@H](O)C1 XAUDJQYHKZQPEU-KVQBGUIXSA-N 0.000 description 9
- 206010009944 Colon cancer Diseases 0.000 description 9
- LFQSCWFLJHTTHZ-UHFFFAOYSA-N Ethanol Chemical compound CCO LFQSCWFLJHTTHZ-UHFFFAOYSA-N 0.000 description 9
- 230000029087 digestion Effects 0.000 description 9
- 108090000765 processed proteins & peptides Proteins 0.000 description 9
- FAPWRFPIFSIZLT-UHFFFAOYSA-M Sodium chloride Chemical compound [Na+].[Cl-] FAPWRFPIFSIZLT-UHFFFAOYSA-M 0.000 description 8
- 230000008774 maternal effect Effects 0.000 description 8
- 102100029457 Adenine phosphoribosyltransferase Human genes 0.000 description 7
- 108010024223 Adenine phosphoribosyltransferase Proteins 0.000 description 7
- 230000001594 aberrant effect Effects 0.000 description 7
- 230000002159 abnormal effect Effects 0.000 description 7
- 210000001072 colon Anatomy 0.000 description 7
- 229920001184 polypeptide Polymers 0.000 description 7
- 102000004196 processed proteins & peptides Human genes 0.000 description 7
- 210000001519 tissue Anatomy 0.000 description 7
- WSFSSNUMVMOOMR-UHFFFAOYSA-N Formaldehyde Chemical compound O=C WSFSSNUMVMOOMR-UHFFFAOYSA-N 0.000 description 6
- 108091092584 GDNA Proteins 0.000 description 6
- 241000699658 Mus musculus domesticus Species 0.000 description 6
- 239000000872 buffer Substances 0.000 description 6
- 238000001415 gene therapy Methods 0.000 description 6
- 125000003729 nucleotide group Chemical group 0.000 description 6
- KCXVZYZYPLLWCC-UHFFFAOYSA-N EDTA Chemical compound OC(=O)CN(CC(O)=O)CCN(CC(O)=O)CC(O)=O KCXVZYZYPLLWCC-UHFFFAOYSA-N 0.000 description 5
- 238000000605 extraction Methods 0.000 description 5
- 210000002950 fibroblast Anatomy 0.000 description 5
- 238000001727 in vivo Methods 0.000 description 5
- 238000003753 real-time PCR Methods 0.000 description 5
- 108091008146 restriction endonucleases Proteins 0.000 description 5
- HEDRZPFGACZZDS-UHFFFAOYSA-N Chloroform Chemical compound ClC(Cl)Cl HEDRZPFGACZZDS-UHFFFAOYSA-N 0.000 description 4
- ISWSIDIOOBJBQZ-UHFFFAOYSA-N Phenol Chemical compound OC1=CC=CC=C1 ISWSIDIOOBJBQZ-UHFFFAOYSA-N 0.000 description 4
- 108091035715 XIST (gene) Proteins 0.000 description 4
- 239000000427 antigen Substances 0.000 description 4
- 108091007433 antigens Proteins 0.000 description 4
- 102000036639 antigens Human genes 0.000 description 4
- 238000013459 approach Methods 0.000 description 4
- 230000006870 function Effects 0.000 description 4
- 238000009396 hybridization Methods 0.000 description 4
- 230000006607 hypermethylation Effects 0.000 description 4
- 125000003835 nucleoside group Chemical group 0.000 description 4
- 239000002773 nucleotide Substances 0.000 description 4
- 238000002360 preparation method Methods 0.000 description 4
- 238000003757 reverse transcription PCR Methods 0.000 description 4
- 238000012216 screening Methods 0.000 description 4
- 239000011780 sodium chloride Substances 0.000 description 4
- 108091032973 (ribonucleotides)n+m Proteins 0.000 description 3
- 108090000790 Enzymes Proteins 0.000 description 3
- 102000004190 Enzymes Human genes 0.000 description 3
- 241000206602 Eukaryota Species 0.000 description 3
- 241000699667 Mus spretus Species 0.000 description 3
- 108091034117 Oligonucleotide Proteins 0.000 description 3
- 102000007354 PAX6 Transcription Factor Human genes 0.000 description 3
- DBMJMQXJHONAFJ-UHFFFAOYSA-M Sodium laurylsulphate Chemical compound [Na+].CCCCCCCCCCCCOS([O-])(=O)=O DBMJMQXJHONAFJ-UHFFFAOYSA-M 0.000 description 3
- 102000044209 Tumor Suppressor Genes Human genes 0.000 description 3
- 108700025716 Tumor Suppressor Genes Proteins 0.000 description 3
- 108091007416 X-inactive specific transcript Proteins 0.000 description 3
- 238000012512 characterization method Methods 0.000 description 3
- 238000006243 chemical reaction Methods 0.000 description 3
- 239000002299 complementary DNA Substances 0.000 description 3
- OPTASPLRGRRNAP-UHFFFAOYSA-N cytosine Chemical compound NC=1C=CNC(=O)N=1 OPTASPLRGRRNAP-UHFFFAOYSA-N 0.000 description 3
- 238000004925 denaturation Methods 0.000 description 3
- 230000036425 denaturation Effects 0.000 description 3
- 238000003745 diagnosis Methods 0.000 description 3
- 238000005516 engineering process Methods 0.000 description 3
- 238000010438 heat treatment Methods 0.000 description 3
- 238000000338 in vitro Methods 0.000 description 3
- 238000002372 labelling Methods 0.000 description 3
- 239000003446 ligand Substances 0.000 description 3
- 239000002502 liposome Substances 0.000 description 3
- 230000004048 modification Effects 0.000 description 3
- 238000012986 modification Methods 0.000 description 3
- 229940126619 mouse monoclonal antibody Drugs 0.000 description 3
- 238000004393 prognosis Methods 0.000 description 3
- 238000000527 sonication Methods 0.000 description 3
- 238000003786 synthesis reaction Methods 0.000 description 3
- QKNYBSVHEMOAJP-UHFFFAOYSA-N 2-amino-2-(hydroxymethyl)propane-1,3-diol;hydron;chloride Chemical compound Cl.OCC(N)(CO)CO QKNYBSVHEMOAJP-UHFFFAOYSA-N 0.000 description 2
- FZWGECJQACGGTI-UHFFFAOYSA-N 2-amino-7-methyl-1,7-dihydro-6H-purin-6-one Chemical compound NC1=NC(O)=C2N(C)C=NC2=N1 FZWGECJQACGGTI-UHFFFAOYSA-N 0.000 description 2
- LRSASMSXMSNRBT-UHFFFAOYSA-N 5-methylcytosine Chemical compound CC1=CNC(=O)N=C1N LRSASMSXMSNRBT-UHFFFAOYSA-N 0.000 description 2
- OGHAROSJZRTIOK-KQYNXXCUSA-O 7-methylguanosine Chemical compound C1=2N=C(N)NC(=O)C=2[N+](C)=CN1[C@@H]1O[C@H](CO)[C@@H](O)[C@H]1O OGHAROSJZRTIOK-KQYNXXCUSA-O 0.000 description 2
- 108091093088 Amplicon Proteins 0.000 description 2
- 108090000565 Capsid Proteins Proteins 0.000 description 2
- 238000000018 DNA microarray Methods 0.000 description 2
- 108010067770 Endopeptidase K Proteins 0.000 description 2
- OAKJQQAXSVQMHS-UHFFFAOYSA-N Hydrazine Chemical compound NN OAKJQQAXSVQMHS-UHFFFAOYSA-N 0.000 description 2
- 108060003951 Immunoglobulin Proteins 0.000 description 2
- 102000001706 Immunoglobulin Fab Fragments Human genes 0.000 description 2
- 108010054477 Immunoglobulin Fab Fragments Proteins 0.000 description 2
- 108010052285 Membrane Proteins Proteins 0.000 description 2
- VQAYFKKCNSOZKM-IOSLPCCCSA-N N(6)-methyladenosine Chemical compound C1=NC=2C(NC)=NC=NC=2N1[C@@H]1O[C@H](CO)[C@@H](O)[C@H]1O VQAYFKKCNSOZKM-IOSLPCCCSA-N 0.000 description 2
- 241000283973 Oryctolagus cuniculus Species 0.000 description 2
- 229910019142 PO4 Inorganic materials 0.000 description 2
- 102000052575 Proto-Oncogene Human genes 0.000 description 2
- 108700020978 Proto-Oncogene Proteins 0.000 description 2
- 108020001027 Ribosomal DNA Proteins 0.000 description 2
- 241000053227 Themus Species 0.000 description 2
- 239000007983 Tris buffer Substances 0.000 description 2
- 229920004890 Triton X-100 Polymers 0.000 description 2
- 239000013504 Triton X-100 Substances 0.000 description 2
- JLCPHMBAVCMARE-UHFFFAOYSA-N [3-[[3-[[3-[[3-[[3-[[3-[[3-[[3-[[3-[[3-[[3-[[5-(2-amino-6-oxo-1H-purin-9-yl)-3-[[3-[[3-[[3-[[3-[[3-[[5-(2-amino-6-oxo-1H-purin-9-yl)-3-[[5-(2-amino-6-oxo-1H-purin-9-yl)-3-hydroxyoxolan-2-yl]methoxy-hydroxyphosphoryl]oxyoxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(5-methyl-2,4-dioxopyrimidin-1-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(6-aminopurin-9-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(6-aminopurin-9-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(6-aminopurin-9-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(6-aminopurin-9-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxyoxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(5-methyl-2,4-dioxopyrimidin-1-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(4-amino-2-oxopyrimidin-1-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(5-methyl-2,4-dioxopyrimidin-1-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(5-methyl-2,4-dioxopyrimidin-1-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(6-aminopurin-9-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(6-aminopurin-9-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(4-amino-2-oxopyrimidin-1-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(4-amino-2-oxopyrimidin-1-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(4-amino-2-oxopyrimidin-1-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(6-aminopurin-9-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(4-amino-2-oxopyrimidin-1-yl)oxolan-2-yl]methyl [5-(6-aminopurin-9-yl)-2-(hydroxymethyl)oxolan-3-yl] hydrogen phosphate Polymers Cc1cn(C2CC(OP(O)(=O)OCC3OC(CC3OP(O)(=O)OCC3OC(CC3O)n3cnc4c3nc(N)[nH]c4=O)n3cnc4c3nc(N)[nH]c4=O)C(COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3CO)n3cnc4c(N)ncnc34)n3ccc(N)nc3=O)n3cnc4c(N)ncnc34)n3ccc(N)nc3=O)n3ccc(N)nc3=O)n3ccc(N)nc3=O)n3cnc4c(N)ncnc34)n3cnc4c(N)ncnc34)n3cc(C)c(=O)[nH]c3=O)n3cc(C)c(=O)[nH]c3=O)n3ccc(N)nc3=O)n3cc(C)c(=O)[nH]c3=O)n3cnc4c3nc(N)[nH]c4=O)n3cnc4c(N)ncnc34)n3cnc4c(N)ncnc34)n3cnc4c(N)ncnc34)n3cnc4c(N)ncnc34)O2)c(=O)[nH]c1=O JLCPHMBAVCMARE-UHFFFAOYSA-N 0.000 description 2
- 230000015572 biosynthetic process Effects 0.000 description 2
- 230000036952 cancer formation Effects 0.000 description 2
- 230000005754 cellular signaling Effects 0.000 description 2
- 238000005119 centrifugation Methods 0.000 description 2
- 239000003795 chemical substances by application Substances 0.000 description 2
- 230000003247 decreasing effect Effects 0.000 description 2
- 238000003795 desorption Methods 0.000 description 2
- 238000009826 distribution Methods 0.000 description 2
- 231100000673 dose–response relationship Toxicity 0.000 description 2
- 238000010201 enrichment analysis Methods 0.000 description 2
- 230000001973 epigenetic effect Effects 0.000 description 2
- 238000002825 functional assay Methods 0.000 description 2
- 102000018358 immunoglobulin Human genes 0.000 description 2
- 239000012742 immunoprecipitation (IP) buffer Substances 0.000 description 2
- NOESYZHRGYRDHS-UHFFFAOYSA-N insulin Chemical compound N1C(=O)C(NC(=O)C(CCC(N)=O)NC(=O)C(CCC(O)=O)NC(=O)C(C(C)C)NC(=O)C(NC(=O)CN)C(C)CC)CSSCC(C(NC(CO)C(=O)NC(CC(C)C)C(=O)NC(CC=2C=CC(O)=CC=2)C(=O)NC(CCC(N)=O)C(=O)NC(CC(C)C)C(=O)NC(CCC(O)=O)C(=O)NC(CC(N)=O)C(=O)NC(CC=2C=CC(O)=CC=2)C(=O)NC(CSSCC(NC(=O)C(C(C)C)NC(=O)C(CC(C)C)NC(=O)C(CC=2C=CC(O)=CC=2)NC(=O)C(CC(C)C)NC(=O)C(C)NC(=O)C(CCC(O)=O)NC(=O)C(C(C)C)NC(=O)C(CC(C)C)NC(=O)C(CC=2NC=NC=2)NC(=O)C(CO)NC(=O)CNC2=O)C(=O)NCC(=O)NC(CCC(O)=O)C(=O)NC(CCCNC(N)=N)C(=O)NCC(=O)NC(CC=3C=CC=CC=3)C(=O)NC(CC=3C=CC=CC=3)C(=O)NC(CC=3C=CC(O)=CC=3)C(=O)NC(C(C)O)C(=O)N3C(CCC3)C(=O)NC(CCCCN)C(=O)NC(C)C(O)=O)C(=O)NC(CC(N)=O)C(O)=O)=O)NC(=O)C(C(C)CC)NC(=O)C(CO)NC(=O)C(C(C)O)NC(=O)C1CSSCC2NC(=O)C(CC(C)C)NC(=O)C(NC(=O)C(CCC(N)=O)NC(=O)C(CC(N)=O)NC(=O)C(NC(=O)C(N)CC=1C=CC=CC=1)C(C)C)CC1=CN=CN1 NOESYZHRGYRDHS-UHFFFAOYSA-N 0.000 description 2
- 230000003834 intracellular effect Effects 0.000 description 2
- 238000000670 ligand binding assay Methods 0.000 description 2
- 238000010208 microarray analysis Methods 0.000 description 2
- 238000010369 molecular cloning Methods 0.000 description 2
- 239000002245 particle Substances 0.000 description 2
- NBIIXXVUZAFLBC-UHFFFAOYSA-K phosphate Chemical compound [O-]P([O-])([O-])=O NBIIXXVUZAFLBC-UHFFFAOYSA-K 0.000 description 2
- 239000010452 phosphate Substances 0.000 description 2
- 239000013641 positive control Substances 0.000 description 2
- 238000001556 precipitation Methods 0.000 description 2
- 230000004952 protein activity Effects 0.000 description 2
- 230000007420 reactivation Effects 0.000 description 2
- 108020003175 receptors Proteins 0.000 description 2
- 102000005962 receptors Human genes 0.000 description 2
- 238000011160 research Methods 0.000 description 2
- 238000012552 review Methods 0.000 description 2
- 230000035945 sensitivity Effects 0.000 description 2
- 239000007790 solid phase Substances 0.000 description 2
- 238000011895 specific detection Methods 0.000 description 2
- 238000001890 transfection Methods 0.000 description 2
- LENZDBCJOHFCAS-UHFFFAOYSA-N tris Chemical compound OCC(N)(CO)CO LENZDBCJOHFCAS-UHFFFAOYSA-N 0.000 description 2
- CKOMXBHMKXXTNW-UHFFFAOYSA-N 6-methyladenine Chemical compound CNC1=NC=NC2=C1N=CN2 CKOMXBHMKXXTNW-UHFFFAOYSA-N 0.000 description 1
- 108010085238 Actins Proteins 0.000 description 1
- 108020004491 Antisense DNA Proteins 0.000 description 1
- 108020005544 Antisense RNA Proteins 0.000 description 1
- 241000894006 Bacteria Species 0.000 description 1
- LSNNMFCWUKXFEE-UHFFFAOYSA-M Bisulfite Chemical compound OS([O-])=O LSNNMFCWUKXFEE-UHFFFAOYSA-M 0.000 description 1
- 206010006187 Breast cancer Diseases 0.000 description 1
- 208000026310 Breast neoplasm Diseases 0.000 description 1
- BHPQYMZQTOCNFJ-UHFFFAOYSA-N Calcium cation Chemical compound [Ca+2] BHPQYMZQTOCNFJ-UHFFFAOYSA-N 0.000 description 1
- 241000283707 Capra Species 0.000 description 1
- 208000005623 Carcinogenesis Diseases 0.000 description 1
- 201000009030 Carcinoma Diseases 0.000 description 1
- 102100023321 Ceruloplasmin Human genes 0.000 description 1
- 241001161843 Chandra Species 0.000 description 1
- IVOMOUWHDPKRLL-KQYNXXCUSA-N Cyclic adenosine monophosphate Chemical compound C([C@H]1O2)OP(O)(=O)O[C@H]1[C@@H](O)[C@@H]2N1C(N=CN=C2N)=C2N=C1 IVOMOUWHDPKRLL-KQYNXXCUSA-N 0.000 description 1
- 230000026641 DNA hypermethylation Effects 0.000 description 1
- 230000008836 DNA modification Effects 0.000 description 1
- 229920002307 Dextran Polymers 0.000 description 1
- 206010061818 Disease progression Diseases 0.000 description 1
- 101150060333 GATA3 gene Proteins 0.000 description 1
- 108700039691 Genetic Promoter Regions Proteins 0.000 description 1
- 108700005087 Homeobox Genes Proteins 0.000 description 1
- 101000635958 Homo sapiens Transforming growth factor beta-2 proprotein Proteins 0.000 description 1
- 102000008394 Immunoglobulin Fragments Human genes 0.000 description 1
- 108010021625 Immunoglobulin Fragments Proteins 0.000 description 1
- 102000006496 Immunoglobulin Heavy Chains Human genes 0.000 description 1
- 108010019476 Immunoglobulin Heavy Chains Proteins 0.000 description 1
- 102000013463 Immunoglobulin Light Chains Human genes 0.000 description 1
- 108010065825 Immunoglobulin Light Chains Proteins 0.000 description 1
- 102000017727 Immunoglobulin Variable Region Human genes 0.000 description 1
- 108010067060 Immunoglobulin Variable Region Proteins 0.000 description 1
- 102000004877 Insulin Human genes 0.000 description 1
- 108090001061 Insulin Proteins 0.000 description 1
- 102000018697 Membrane Proteins Human genes 0.000 description 1
- 241001465754 Metazoa Species 0.000 description 1
- 239000000020 Nitrocellulose Substances 0.000 description 1
- 238000012408 PCR amplification Methods 0.000 description 1
- 241001494479 Pecora Species 0.000 description 1
- 238000011530 RNeasy Mini Kit Methods 0.000 description 1
- 238000012300 Sequence Analysis Methods 0.000 description 1
- 102100030737 Transforming growth factor beta-2 proprotein Human genes 0.000 description 1
- IVOMOUWHDPKRLL-UHFFFAOYSA-N UNPD107823 Natural products O1C2COP(O)(=O)OC2C(O)C1N1C(N=CN=C2N)=C2N=C1 IVOMOUWHDPKRLL-UHFFFAOYSA-N 0.000 description 1
- 101710100170 Unknown protein Proteins 0.000 description 1
- 238000009825 accumulation Methods 0.000 description 1
- 208000009956 adenocarcinoma Diseases 0.000 description 1
- 150000003838 adenosines Chemical class 0.000 description 1
- 239000011543 agarose gel Substances 0.000 description 1
- 230000032683 aging Effects 0.000 description 1
- 230000004075 alteration Effects 0.000 description 1
- 230000000692 anti-sense effect Effects 0.000 description 1
- 239000002246 antineoplastic agent Substances 0.000 description 1
- 239000003816 antisense DNA Substances 0.000 description 1
- 239000000074 antisense oligonucleotide Substances 0.000 description 1
- 238000012230 antisense oligonucleotides Methods 0.000 description 1
- 230000006907 apoptotic process Effects 0.000 description 1
- 239000008346 aqueous phase Substances 0.000 description 1
- 230000008827 biological function Effects 0.000 description 1
- 230000033228 biological regulation Effects 0.000 description 1
- 229940098773 bovine serum albumin Drugs 0.000 description 1
- 238000010804 cDNA synthesis Methods 0.000 description 1
- 229910001424 calcium ion Inorganic materials 0.000 description 1
- 239000001506 calcium phosphate Substances 0.000 description 1
- 229910000389 calcium phosphate Inorganic materials 0.000 description 1
- 235000011010 calcium phosphates Nutrition 0.000 description 1
- 230000006369 cell cycle progression Effects 0.000 description 1
- 230000032823 cell division Effects 0.000 description 1
- 230000003915 cell function Effects 0.000 description 1
- 230000007910 cell fusion Effects 0.000 description 1
- 230000008619 cell matrix interaction Effects 0.000 description 1
- 210000000170 cell membrane Anatomy 0.000 description 1
- 230000030570 cellular localization Effects 0.000 description 1
- 230000008859 change Effects 0.000 description 1
- 230000002759 chromosomal effect Effects 0.000 description 1
- 210000000349 chromosome Anatomy 0.000 description 1
- 238000010367 cloning Methods 0.000 description 1
- 238000012733 comparative method Methods 0.000 description 1
- 239000003184 complementary RNA Substances 0.000 description 1
- 150000001875 compounds Chemical class 0.000 description 1
- 238000004624 confocal microscopy Methods 0.000 description 1
- 238000007796 conventional method Methods 0.000 description 1
- 238000002425 crystallisation Methods 0.000 description 1
- 230000008025 crystallization Effects 0.000 description 1
- 210000004748 cultured cell Anatomy 0.000 description 1
- 229940095074 cyclic amp Drugs 0.000 description 1
- 230000001351 cycling effect Effects 0.000 description 1
- UHDGCWIWMRVCDJ-ZAKLUEHWSA-N cytidine Chemical class O=C1N=C(N)C=CN1[C@H]1[C@H](O)[C@@H](O)[C@H](CO)O1 UHDGCWIWMRVCDJ-ZAKLUEHWSA-N 0.000 description 1
- 229940104302 cytosine Drugs 0.000 description 1
- SUYVUBYJARFZHO-RRKCRQDMSA-N dATP Chemical compound C1=NC=2C(N)=NC=NC=2N1[C@H]1C[C@H](O)[C@@H](COP(O)(=O)OP(O)(=O)OP(O)(O)=O)O1 SUYVUBYJARFZHO-RRKCRQDMSA-N 0.000 description 1
- SUYVUBYJARFZHO-UHFFFAOYSA-N dATP Natural products C1=NC=2C(N)=NC=NC=2N1C1CC(O)C(COP(O)(=O)OP(O)(=O)OP(O)(O)=O)O1 SUYVUBYJARFZHO-UHFFFAOYSA-N 0.000 description 1
- RGWHQCVHVJXOKC-SHYZEUOFSA-J dCTP(4-) Chemical compound O=C1N=C(N)C=CN1[C@@H]1O[C@H](COP([O-])(=O)OP([O-])(=O)OP([O-])([O-])=O)[C@@H](O)C1 RGWHQCVHVJXOKC-SHYZEUOFSA-J 0.000 description 1
- HAAZLUGHYHWQIW-KVQBGUIXSA-N dGTP Chemical compound C1=NC=2C(=O)NC(N)=NC=2N1[C@H]1C[C@H](O)[C@@H](COP(O)(=O)OP(O)(=O)OP(O)(O)=O)O1 HAAZLUGHYHWQIW-KVQBGUIXSA-N 0.000 description 1
- NHVNXKFIZYSCEB-XLPZGREQSA-N dTTP Chemical compound O=C1NC(=O)C(C)=CN1[C@@H]1O[C@H](COP(O)(=O)OP(O)(=O)OP(O)(O)=O)[C@@H](O)C1 NHVNXKFIZYSCEB-XLPZGREQSA-N 0.000 description 1
- 230000002950 deficient Effects 0.000 description 1
- 239000012649 demethylating agent Substances 0.000 description 1
- 239000000539 dimer Substances 0.000 description 1
- 230000005750 disease progression Effects 0.000 description 1
- 230000003828 downregulation Effects 0.000 description 1
- 239000003814 drug Substances 0.000 description 1
- 229940000406 drug candidate Drugs 0.000 description 1
- 238000007876 drug discovery Methods 0.000 description 1
- 238000007877 drug screening Methods 0.000 description 1
- 239000003596 drug target Substances 0.000 description 1
- 238000004520 electroporation Methods 0.000 description 1
- 230000012202 endocytosis Effects 0.000 description 1
- 230000002255 enzymatic effect Effects 0.000 description 1
- 238000012869 ethanol precipitation Methods 0.000 description 1
- ZMMJGEGLRURXTF-UHFFFAOYSA-N ethidium bromide Chemical compound [Br-].C12=CC(N)=CC=C2C2=CC=C(N)C=C2[N+](CC)=C1C1=CC=CC=C1 ZMMJGEGLRURXTF-UHFFFAOYSA-N 0.000 description 1
- 229960005542 ethidium bromide Drugs 0.000 description 1
- 238000001914 filtration Methods 0.000 description 1
- 230000004927 fusion Effects 0.000 description 1
- 238000011331 genomic analysis Methods 0.000 description 1
- 239000011521 glass Substances 0.000 description 1
- 239000003102 growth factor Substances 0.000 description 1
- 239000001963 growth medium Substances 0.000 description 1
- 238000010166 immunofluorescence Methods 0.000 description 1
- 238000001114 immunoprecipitation Methods 0.000 description 1
- 238000010348 incorporation Methods 0.000 description 1
- 239000003112 inhibitor Substances 0.000 description 1
- 229940125396 insulin Drugs 0.000 description 1
- 150000002500 ions Chemical class 0.000 description 1
- 238000002955 isolation Methods 0.000 description 1
- 230000002045 lasting effect Effects 0.000 description 1
- 239000007788 liquid Substances 0.000 description 1
- 210000004072 lung Anatomy 0.000 description 1
- 230000003211 malignant effect Effects 0.000 description 1
- 210000004962 mammalian cell Anatomy 0.000 description 1
- 210000000415 mammalian chromosome Anatomy 0.000 description 1
- 238000004519 manufacturing process Methods 0.000 description 1
- 239000000463 material Substances 0.000 description 1
- 230000001404 mediated effect Effects 0.000 description 1
- 239000002609 medium Substances 0.000 description 1
- 108020004999 messenger RNA Proteins 0.000 description 1
- 238000000520 microinjection Methods 0.000 description 1
- 238000002715 modification method Methods 0.000 description 1
- 239000013642 negative control Substances 0.000 description 1
- 239000002547 new drug Substances 0.000 description 1
- 229920001220 nitrocellulos Polymers 0.000 description 1
- 238000002966 oligonucleotide array Methods 0.000 description 1
- 230000037361 pathway Effects 0.000 description 1
- 239000008188 pellet Substances 0.000 description 1
- 230000035515 penetration Effects 0.000 description 1
- 150000004713 phosphodiesters Chemical group 0.000 description 1
- 230000037452 priming Effects 0.000 description 1
- 238000012545 processing Methods 0.000 description 1
- 238000002731 protein assay Methods 0.000 description 1
- 230000010837 receptor-mediated endocytosis Effects 0.000 description 1
- 230000009467 reduction Effects 0.000 description 1
- 230000001177 retroviral effect Effects 0.000 description 1
- 230000002441 reversible effect Effects 0.000 description 1
- 150000003839 salts Chemical class 0.000 description 1
- 238000010008 shearing Methods 0.000 description 1
- 239000011734 sodium Substances 0.000 description 1
- 239000001488 sodium phosphate Substances 0.000 description 1
- 229910000162 sodium phosphate Inorganic materials 0.000 description 1
- 230000009870 specific binding Effects 0.000 description 1
- 238000003860 storage Methods 0.000 description 1
- 230000008685 targeting Effects 0.000 description 1
- 238000012360 testing method Methods 0.000 description 1
- 229940124597 therapeutic agent Drugs 0.000 description 1
- 238000013518 transcription Methods 0.000 description 1
- 230000035897 transcription Effects 0.000 description 1
- 230000037426 transcriptional repression Effects 0.000 description 1
- 238000012546 transfer Methods 0.000 description 1
- QORWJWZARLRLPR-UHFFFAOYSA-H tricalcium bis(phosphate) Chemical compound [Ca+2].[Ca+2].[Ca+2].[O-]P([O-])([O-])=O.[O-]P([O-])([O-])=O QORWJWZARLRLPR-UHFFFAOYSA-H 0.000 description 1
- RYFMWSXOAZQYPI-UHFFFAOYSA-K trisodium phosphate Chemical compound [Na+].[Na+].[Na+].[O-]P([O-])([O-])=O RYFMWSXOAZQYPI-UHFFFAOYSA-K 0.000 description 1
- 230000036325 urinary excretion Effects 0.000 description 1
- 230000003612 virological effect Effects 0.000 description 1
Images
Classifications
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
- C12N15/09—Recombinant DNA-technology
- C12N15/10—Processes for the isolation, preparation or purification of DNA or RNA
- C12N15/1003—Extracting or separating nucleic acids from biological samples, e.g. pure separation or isolation methods; Conditions, buffers or apparatuses therefor
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
Landscapes
- Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Engineering & Computer Science (AREA)
- Life Sciences & Earth Sciences (AREA)
- Genetics & Genomics (AREA)
- Biomedical Technology (AREA)
- Organic Chemistry (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Wood Science & Technology (AREA)
- Zoology (AREA)
- General Engineering & Computer Science (AREA)
- Biotechnology (AREA)
- General Health & Medical Sciences (AREA)
- Molecular Biology (AREA)
- Analytical Chemistry (AREA)
- Biochemistry (AREA)
- Crystallography & Structural Chemistry (AREA)
- Physics & Mathematics (AREA)
- Biophysics (AREA)
- Plant Pathology (AREA)
- Microbiology (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Veterinary Medicine (AREA)
- General Chemical & Material Sciences (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Public Health (AREA)
- Pharmacology & Pharmacy (AREA)
- Animal Behavior & Ethology (AREA)
- Medicinal Chemistry (AREA)
- Measuring Or Testing Involving Enzymes Or Micro-Organisms (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Medicines Containing Material From Animals Or Micro-Organisms (AREA)
- Peptides Or Proteins (AREA)
Applications Claiming Priority (2)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| GBGB0413688.3A GB0413688D0 (en) | 2004-06-18 | 2004-06-18 | Analysis of methylated nucleic acid |
| PCT/EP2005/002251 WO2005123942A2 (en) | 2004-06-18 | 2005-03-03 | Analysis of methylated nucleic acid |
Publications (2)
| Publication Number | Publication Date |
|---|---|
| JP2008502332A true JP2008502332A (ja) | 2008-01-31 |
| JP2008502332A5 JP2008502332A5 (enExample) | 2008-04-17 |
Family
ID=32750180
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2007515787A Pending JP2008502332A (ja) | 2004-06-18 | 2005-03-03 | メチル化核酸の分析 |
Country Status (8)
| Country | Link |
|---|---|
| US (2) | US20090270482A1 (enExample) |
| EP (1) | EP1761639B1 (enExample) |
| JP (1) | JP2008502332A (enExample) |
| AU (2) | AU2005254616A1 (enExample) |
| CA (1) | CA2568575A1 (enExample) |
| ES (1) | ES2401110T3 (enExample) |
| GB (1) | GB0413688D0 (enExample) |
| WO (1) | WO2005123942A2 (enExample) |
Cited By (6)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| JP2012523822A (ja) * | 2009-04-17 | 2012-10-11 | ▲頼▼鴻政 | 癌検診の方法 |
| JP2013044698A (ja) * | 2011-08-26 | 2013-03-04 | Tohoku Univ | 細胞ストレス状態のバイオマーカー |
| JP2013517789A (ja) * | 2010-01-26 | 2013-05-20 | ニプド ジェネティクス リミテッド | 胎児異数性の非侵襲性出生前診断の方法および組成物 |
| KR101735415B1 (ko) * | 2015-07-31 | 2017-05-16 | 한국과학기술연구원 | 헥산알 노출 특이적 메틸화 마커 유전자 및 이를 이용한 확인 방법 |
| WO2017130839A1 (ja) * | 2016-01-27 | 2017-08-03 | 住友化学株式会社 | センサーチップ及びセンシングシステム |
| US11111538B2 (en) | 2015-05-22 | 2021-09-07 | Nipd Genetics Public Company Ltd | Multiplexed parallel analysis of targeted genomic regions for non-invasive prenatal testing |
Families Citing this family (13)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| DE102005034628B4 (de) * | 2005-07-19 | 2007-08-23 | Epigenomics Ag | Verfahren zur Untersuchung von Cytosin-Methylierungen in DNA |
| EP1862555A1 (en) * | 2006-05-29 | 2007-12-05 | Klinikum der Universität Regensburg | Means and methods for diagnosing cancer or a corresponding predisposition |
| US20120196827A1 (en) * | 2006-06-12 | 2012-08-02 | Oncomethylome Sciences S.A. | Methylation markers for early detection and prognosis of colon cancers |
| CN102099485A (zh) * | 2007-10-23 | 2011-06-15 | 临床基因组学有限公司 | 诊断新生物的方法-ⅱ |
| JP2009247260A (ja) * | 2008-04-04 | 2009-10-29 | Sumitomo Chemical Co Ltd | Ｄｎａメチル化測定方法 |
| US8278049B2 (en) | 2010-04-26 | 2012-10-02 | Ann & Robert H. Lurie Children's Hospital of Chicago | Selective enrichment of CpG islands |
| US20120004132A1 (en) * | 2010-07-02 | 2012-01-05 | Affymetrix, Inc. | Detection of Nucleic Acids and Proteins |
| WO2013123481A1 (en) | 2012-02-16 | 2013-08-22 | Cornell University | Methods and kit for characterizing the modified base status of a transcriptome |
| US20160202249A1 (en) * | 2013-08-21 | 2016-07-14 | Fujirebio Inc. | Method for measuring modified nucleobase using absorbent polynucleotide and kit for same |
| US10975417B2 (en) * | 2016-02-23 | 2021-04-13 | Dovetail Genomics, Llc | Generation of phased read-sets for genome assembly and haplotype phasing |
| JP7457642B2 (ja) | 2017-04-03 | 2024-03-28 | ビオンテック ユーエス インコーポレイテッド | タンパク質抗原およびその使用 |
| TW201930340A (zh) | 2017-12-18 | 2019-08-01 | 美商尼恩醫療公司 | 新抗原及其用途 |
| CA3103983A1 (en) | 2018-06-19 | 2019-12-26 | Biontech Us Inc. | Neoantigens and uses thereof |
Citations (6)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| WO2002000842A2 (en) * | 2000-06-23 | 2002-01-03 | The University Of Chicago | Methods for isolating centromere dna |
| WO2002101353A2 (en) * | 2001-06-08 | 2002-12-19 | U.S. Genomics, Inc. | Methods and products for analyzing nucleic acids based on methylation status |
| WO2004033683A1 (de) * | 2002-09-18 | 2004-04-22 | Sirs-Lab Gmbh | Verfahren zur anreicherung prokaryontischer dna |
| WO2004065625A1 (en) * | 2003-01-24 | 2004-08-05 | Human Genetic Signatures Pty Ltd | Assay for detecting methylation changes in nucleic acids using an intercalating nucleic acid |
| JP2004347508A (ja) * | 2003-05-23 | 2004-12-09 | Japan Science & Technology Agency | Ｄｎａメチル化率の測定方法 |
| WO2005080565A1 (ja) * | 2004-02-20 | 2005-09-01 | Japan Science And Technology Agency | Ｄｎａメチル化分析用ｄｎａアレイ及びその製造方法並びにｄｎａメチル化分析方法 |
Family Cites Families (11)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US5654183A (en) * | 1992-07-27 | 1997-08-05 | California Institute Of Technology | Genetically engineered mammalian neural crest stem cells |
| US5518901A (en) * | 1993-04-19 | 1996-05-21 | Murtagh; James J. | Methods for adapting nucleic acid for detection, sequencing, and cloning using exonuclease |
| US5714325A (en) * | 1993-09-24 | 1998-02-03 | New England Medical Center Hospitals | Prenatal diagnosis by isolation of fetal granulocytes from maternal blood |
| US5866323A (en) * | 1995-04-07 | 1999-02-02 | Case Western Reserve University | Cancer diagnosis prognosis and therapy based on mutation of receptors for transforming growth factor β and homologous growth controlling factors |
| AU7829398A (en) * | 1997-06-09 | 1998-12-30 | University Of Southern California | A cancer diagnostic method based upon dna methylation differences |
| US6337392B1 (en) * | 1998-05-07 | 2002-01-08 | The Rockefeller University | Lens transcriptional control elements and methods of use thereof |
| US6994971B1 (en) * | 1999-10-08 | 2006-02-07 | University Of Utah Research Foundation | Particle analysis assay for biomolecular quantification |
| MXPA02005069A (es) * | 1999-11-19 | 2003-09-25 | Wegmann Keith W | Agentes de enlace especificos para t3 y metodos para su uso. |
| US20030157481A1 (en) * | 2001-12-10 | 2003-08-21 | Benjamin Thomas L. | Diagnosing and treating cancer cells using T-HR mutants and their targets |
| AU2003206443A1 (en) * | 2002-02-20 | 2003-09-09 | Academisch Ziekenhuis Bij De Universiteit Van Amsterdam | Hedgehog-related prophylaxis, therapy and diagnosis of gi tract carcinogenesis |
| EP1524523A1 (en) * | 2003-10-17 | 2005-04-20 | Deutsches Krebsforschungszentrum Stiftung Des Öffentlichen Rechts | Use of ADAM 12 for diagnosis and therapy of preeclampsia |
-
2004
- 2004-06-18 GB GBGB0413688.3A patent/GB0413688D0/en not_active Ceased
-
2005
- 2005-03-03 US US11/571,026 patent/US20090270482A1/en not_active Abandoned
- 2005-03-03 WO PCT/EP2005/002251 patent/WO2005123942A2/en not_active Ceased
- 2005-03-03 AU AU2005254616A patent/AU2005254616A1/en not_active Abandoned
- 2005-03-03 EP EP05707697A patent/EP1761639B1/en not_active Expired - Lifetime
- 2005-03-03 ES ES05707697T patent/ES2401110T3/es not_active Expired - Lifetime
- 2005-03-03 JP JP2007515787A patent/JP2008502332A/ja active Pending
- 2005-03-03 CA CA002568575A patent/CA2568575A1/en not_active Abandoned
-
2009
- 2009-07-07 AU AU2009202745A patent/AU2009202745A1/en not_active Ceased
-
2012
- 2012-05-03 US US13/463,570 patent/US20120288509A1/en not_active Abandoned
Patent Citations (6)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| WO2002000842A2 (en) * | 2000-06-23 | 2002-01-03 | The University Of Chicago | Methods for isolating centromere dna |
| WO2002101353A2 (en) * | 2001-06-08 | 2002-12-19 | U.S. Genomics, Inc. | Methods and products for analyzing nucleic acids based on methylation status |
| WO2004033683A1 (de) * | 2002-09-18 | 2004-04-22 | Sirs-Lab Gmbh | Verfahren zur anreicherung prokaryontischer dna |
| WO2004065625A1 (en) * | 2003-01-24 | 2004-08-05 | Human Genetic Signatures Pty Ltd | Assay for detecting methylation changes in nucleic acids using an intercalating nucleic acid |
| JP2004347508A (ja) * | 2003-05-23 | 2004-12-09 | Japan Science & Technology Agency | Ｄｎａメチル化率の測定方法 |
| WO2005080565A1 (ja) * | 2004-02-20 | 2005-09-01 | Japan Science And Technology Agency | Ｄｎａメチル化分析用ｄｎａアレイ及びその製造方法並びにｄｎａメチル化分析方法 |
Cited By (10)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| JP2012523822A (ja) * | 2009-04-17 | 2012-10-11 | ▲頼▼鴻政 | 癌検診の方法 |
| JP2013517789A (ja) * | 2010-01-26 | 2013-05-20 | ニプド ジェネティクス リミテッド | 胎児異数性の非侵襲性出生前診断の方法および組成物 |
| US9249462B2 (en) | 2010-01-26 | 2016-02-02 | Nipd Genetics Ltd | Methods and compositions for noninvasive prenatal diagnosis of fetal aneuploidies |
| JP2013044698A (ja) * | 2011-08-26 | 2013-03-04 | Tohoku Univ | 細胞ストレス状態のバイオマーカー |
| US11111538B2 (en) | 2015-05-22 | 2021-09-07 | Nipd Genetics Public Company Ltd | Multiplexed parallel analysis of targeted genomic regions for non-invasive prenatal testing |
| US12421551B2 (en) | 2015-05-22 | 2025-09-23 | Medicover Public Co Ltd | Multiplexed parallel analysis of targeted genomic regions for non-invasive prenatal testing |
| US12480160B2 (en) | 2015-05-22 | 2025-11-25 | Medicover Public Co Ltd | Multiplexed parallel analysis of targeted genomic regions for non-invasive prenatal testing |
| KR101735415B1 (ko) * | 2015-07-31 | 2017-05-16 | 한국과학기술연구원 | 헥산알 노출 특이적 메틸화 마커 유전자 및 이를 이용한 확인 방법 |
| WO2017130839A1 (ja) * | 2016-01-27 | 2017-08-03 | 住友化学株式会社 | センサーチップ及びセンシングシステム |
| JPWO2017130839A1 (ja) * | 2016-01-27 | 2018-11-22 | 住友化学株式会社 | センサーチップ及びセンシングシステム |
Also Published As
| Publication number | Publication date |
|---|---|
| CA2568575A1 (en) | 2005-12-29 |
| US20120288509A1 (en) | 2012-11-15 |
| AU2005254616A1 (en) | 2005-12-29 |
| ES2401110T3 (es) | 2013-04-17 |
| GB0413688D0 (en) | 2004-07-21 |
| US20090270482A1 (en) | 2009-10-29 |
| WO2005123942A3 (en) | 2006-04-13 |
| EP1761639A2 (en) | 2007-03-14 |
| EP1761639B1 (en) | 2013-01-02 |
| WO2005123942A2 (en) | 2005-12-29 |
| AU2009202745A1 (en) | 2009-07-30 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| US20120288509A1 (en) | Analysis of methylated nucleic acid | |
| US11261497B2 (en) | PRKC fusions | |
| US10407509B2 (en) | NTRK2 fusions | |
| US10669590B2 (en) | PIK3CA fusions | |
| US10246750B2 (en) | Method for detection of a TECR:PKN1 or an ANXA4:PKN1 gene fusion | |
| CN107586835B (zh) | 一种基于单链接头的下一代测序文库的构建方法及其应用 | |
| US20220205045A1 (en) | Raf1 fusions | |
| EP3221700B1 (en) | Prkacb fusions | |
| US10370725B2 (en) | FGR fusions | |
| US10875930B2 (en) | PIK3C2G fusions | |
| US20170044621A1 (en) | Met fusions | |
| Keuthan et al. | Alternative RNA splicing in the retina: insights and perspectives | |
| AU2011203953B2 (en) | Analysis of methylated nucleic acid | |
| Keane | Molecular and genetic studies of DLG2 in neuroblastoma and colorectal cancer | |
| EP4476353A1 (en) | Method for the manufacture of a viral system, a vector system or any transport system for cancer-specific crispr complexes | |
| Borecká | Role of genetic factors responsible for development of pancreatic cancer | |
| Ye | Serial analysis of gene expression in human diseases |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| A521 | Request for written amendment filed |
Free format text: JAPANESE INTERMEDIATE CODE: A523 Effective date: 20080226 |
|
| A621 | Written request for application examination |
Free format text: JAPANESE INTERMEDIATE CODE: A621 Effective date: 20080226 |
|
| A131 | Notification of reasons for refusal |
Free format text: JAPANESE INTERMEDIATE CODE: A131 Effective date: 20101019 |
|
| A601 | Written request for extension of time |
Free format text: JAPANESE INTERMEDIATE CODE: A601 Effective date: 20110119 |
|
| A602 | Written permission of extension of time |
Free format text: JAPANESE INTERMEDIATE CODE: A602 Effective date: 20110126 |
|
| A601 | Written request for extension of time |
Free format text: JAPANESE INTERMEDIATE CODE: A601 Effective date: 20110218 |
|
| A602 | Written permission of extension of time |
Free format text: JAPANESE INTERMEDIATE CODE: A602 Effective date: 20110225 |
|
| A601 | Written request for extension of time |
Free format text: JAPANESE INTERMEDIATE CODE: A601 Effective date: 20110322 |
|
| A602 | Written permission of extension of time |
Free format text: JAPANESE INTERMEDIATE CODE: A602 Effective date: 20110329 |
|
| A02 | Decision of refusal |
Free format text: JAPANESE INTERMEDIATE CODE: A02 Effective date: 20110712 |